Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Could Kenvue Follow in the Footsteps of Johnson & Johnson and Become a Top Dividend Stock?
06:00am, Sunday, 01'st Oct 2023
J&J recently spun off its billion-dollar consumer health business to form Kenvue. Kenvue announced a dividend during its first earnings report as an independent entity.
Recession-Proof Royals: 3 Stocks That Thrive in Tough Economic Times
08:31am, Friday, 29'th Sep 2023
In the new century, economic uncertainty often looms. Finding investment opportunities that can weather the storm is a quest every investor undertakes.
Don't Miss Out: 3 Dividend Stocks to Buy on EVERY. SINGLE. DIP.
08:12am, Friday, 29'th Sep 2023
There is no better way to create wealth than investing in stocks. Not gold, not bonds, not real estate.
Unitaid urges Johnson & Johnson to improve access to TB drug bedaquiline
04:36am, Friday, 29'th Sep 2023
Global health aid agency Unitaid has written to Johnson & Johnson's (J&J) CEO Joaquin Duato, urging him to take "immediate action" to expand access to the company's tuberculosis drug bedaquiline.
J&J's lung cancer therapy combo succeeds in late-stage study
07:37am, Thursday, 28'th Sep 2023
Johnson & Johnson said on Thursday its cancer therapy combination met the main goal in a late-stage study testing it as a treatment for patients with a type of lung cancer.
3 Things About Johnson & Johnson That Smart Investors Know
05:30am, Wednesday, 27'th Sep 2023
J&J recently spun off its slowest-growing business -- consumer health. The healthcare giant aims to focus its resources in its pharmaceuticals and medtech units, which together generated more than $79
2 Monster Stocks to Buy Without Any Hesitation
07:41am, Tuesday, 26'th Sep 2023
Johnson & Johnson and Intuitive Surgical are both leaders in their industries and long-time market beaters. Johnson & Johnson has a knack for developing new medicines, a solid balance sheet, and a sec
3 Blue Chip Safe Havens to Shield Your Portfolio
06:59am, Monday, 25'th Sep 2023
The market had one of its worst weeks of the year, as the SPDR S&P 500 ETF Trust NYSE: SPY tumbled almost 3% lower. The selloff swept the market last week after the Federal Reserve signaled that inter
Johnson & Johnson: The Bull Case Can No Longer Be Ignored
08:30am, Saturday, 23'rd Sep 2023
J&J's stock fell steeply following its share exchange offer for Kenvue stock, but dip buyers have since returned, auguring well for a further recovery. JNJ's best-in-class "A+" profitability grade pro
The Buffett List: 5 Dividend Buys For September
03:53pm, Friday, 22'nd Sep 2023
This Buffett holdings-list from Kiplinger first appeared 8/21/23 on line. Kiplinger, YCharts and Dogs of The Dow all track this Buffett/Berkshire batch. Here is your update from 9/20/23 YCharts data.
Protagonist Therapeutics: There Are Reasons Behind Johnson & Johnson's Optimism
03:35pm, Friday, 22'nd Sep 2023
Protagonist Therapeutics, Inc.'s oral IL-23 drug for psoriasis, JNJ-2113, must show non-inferior efficacy to Johnson & Johnson's injectable Tremfya before further development. JNJ-2113 is the only ora
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
10:31am, Friday, 22'nd Sep 2023
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here are the 14 stocks Jim Cramer is watching, including Apple, Goldman Sachs, Amazon
09:41am, Wednesday, 20'th Sep 2023
Here are some of the tickers on my radar for Wednesday, Sept. 20, taken directly from my reporter's notebook.
Flee to Healthcare Stocks if Recession Rears its Head?
07:04am, Wednesday, 20'th Sep 2023
If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.
7 Safe and Steady Dividend Stocks to Buy for Volatile Time
11:36am, Tuesday, 19'th Sep 2023
Navigating the unpredictable waters of today's market, safe dividend stocks emerge as a beacon of reliability. Despite an optimistic kickoff this year, the broader market sentiment has chilled.
